Skip to main content

Home/ MaRS/ Group items tagged Canadian Venture Capital Association

Rss Feed Group items tagged

Assunta Krehl

MaRS makes its first foray into the cleantech spotlight - Cleantech Group - 0 views

  • Five cleantech companies receive support at the Cleantech Forum in Boston from Canadian incubation and innovation center MaRS.
  • Alternative Fuels was just one of a lineup of early-stage startups being supported by MaRS, a nonprofit innovation center in Toronto’s downtown Discovery District that connects entrepreneurs with business skills, networks and capital to stimulate innovation and grow Canadian companies.
  • This week’s forum marked the organization’s first foray into the cleantech sector, said MaRS Venture Group Associate Kevin Downing. Downing said he wanted to connect cleantech-related companies in the MaRS portfolio that were “investment ready” with the forum’s audience. “I don’t have a motive to push any one client over any other because they’re not paying me,” Downing said. Of the 1,300 MaRS portfolio companies, he said the cleantech sector has been its fastest growing segment and an expanding sector in country as well (see Canadian cleantech looks to the future and IPO drought? Cleantech companies flood Canadian markets). Since 2006, cleantech and environmental technology companies have made up 9 percent of MaRS' portfolio. MaRS currently has 350 active clients. The center isn’t government funded, but does receive some government support, he said. It has been funded through donations from the public and private sector. MaRS has the ability to provide some funding, around $40,000, to startups on a competitive basis. Other companies showcased at the forum through MaRS included NIMtech, Real Tech, Vicicog and Skymeter.
  • ...1 more annotation...
  • This week’s forum marked the organization’s first foray into the cleantech sector, said MaRS Venture Group Associate Kevin Downing. Downing said he wanted to connect cleantech-related companies in the MaRS portfolio that were “investment ready” with the forum’s audience. “I don’t have a motive to push any one client over any other because they’re not paying me,” Downing said. Of the 1,300 MaRS portfolio companies, he said the cleantech sector has been its fastest growing segment and an expanding sector in country as well (see Canadian cleantech looks to the future and IPO drought? Cleantech companies flood Canadian markets). Since 2006, cleantech and environmental technology companies have made up 9 percent of MaRS' portfolio. MaRS currently has 350 active clients. The center isn’t government funded, but does receive some government support, he said. It has been funded through donations from the public and private sector, as well as revenue from its mixed-use facility. MaRS has the ability to provide some funding, around $40,000, to startups on a competitive basis. Other companies showcased at the forum through MaRS included NIMtech, Real Tech, Vicicog and Skymeter.
  •  
    Five cleantech companies received support at the Cleantech Forum in Boston from Canadian incubation and innovation center MaRS. Some of the companies showcased at the forum through MaRS included NIMtech, Real Tech, Vicicog and Skymeter. Sept 10, 2009
Assunta Krehl

Timing is everything - Progress Magazine - September 21, 2011 - 0 views

  •  
    Peter Moreira states "Canada badly needs to develop its VC industry." Canadian Venture Capital and Private Equity Association is a MaRS Discovery District tenant as is working to increase venture capitalist across Canada.
Assunta Krehl

Pharmafocus.com - 0 views

  • Canada has always had to fight hard to attract talent and investment
  • MaRS Vital to Toronto's life sciences vision is MaRS (derived from Medical and Related Sciences) a non-profit organisation and business centre located in the heart of the city. Its core function is as a biotech incubator and business park, known as MaRS Discovery District. The venture was first established in 2000 to help foster and accelerate the growth of successful Canadian businesses and, after some uncertain times, it is now gathering momentum. A separate technology transfer office, MaRS Innovation, has also been established that, it is hoped, can be a world beater in its own right (see Turning good ideas into world beaters below). The location of the MaRS building in central Toronto is important, as it is just a stone's throw away from an existing cluster of universities and academic hospitals. MaRS has many links with other research-based organisations, including collaborations with three local universities, 10 academic teaching hospitals and the Ontario Institute for Cancer Research. MaRS occupies the Old Toronto general hospital, where insulin was first discovered by Best and Banting in 1921 and then developed for use in human trials. The 21st Century organisation can build on this heritage in patient-focused discovery and development. Formerly the head of venture capital firm Primaxis, Ilse Treurnicht is chief executive of MaRS Discovery District. She acknowledges the crisis in venture capital funding, and says Canada's sector has always had less access funds through this route than other countries. This is one of the drivers behind the search for a new approach. Treurnicht says the old models of building biotech and life sciences businesses have to be discarded, as they have failed to build companies with critical mass. She says MaRS' new 'Convergence Innovation' strategy of bringing science, capital and business together will pay off.
  • "We call our strategy 'Convergence Innovation' and what we are trying to do is move away from the old linear model of academics struggling in their spare time to build companies or entrepreneurs doing this in a very incremental way."It takes time and it has many risk points along the way. So using this Convergence centre model to create a much more dynamic organisation which can help accelerate good ideas towards the commercialisation." But she says Canada's geography and demographics are always going to be a challenge. "This is a very large country with a small population. If you think in terms of clusters and hub regions, Canada's business hubs are separated geographically, and there is not much in between in terms of people."That means we can't try to be a little United States, because we just won't show up on the radar. We have to take a different approach. We have to think about collaboration as our potential competitive advantage - that means using networks and associations to solve problems and build businesses."So as new opportunities emerge, we can take them to market faster and hopefully with a higher success rate." The centre currently accommodates numerous start up companies, as well as those providing legal and financial services to them. AstraZeneca and GlaxoSmithKline also have offices on site. In all, MaRS provides mentoring for over 200 different companies across Ontario, and runs courses on entrepreneurship and preparing products for market.
  • ...7 more annotations...
  • Transition Therapeutics is one of the companies based at MaRS, and is an example of a biopharmaceutical company that is taking a new approach to the science and business of drug development.
  • Now Toronto's MaRS Innovation (MI) has been launched to try to guide and accelerate these promising ideas out of the wilderness and onto the market. MI is a not-for-profit technology transfer company that will channel all the best ideas to come out of Toronto's renowned academic centres. In the Toronto and Ontario area there were between 14-16 different technology transfer offices in the different institutions, and MaRS Innovation resolved to bring these interests together into a single entity after industry partners told them it was an inefficient way to do business. Bringing together the different institutions under one umbrella organisation has been an arduous task for MaRS, but the reward could be considerable for all parties. MI now oversees probably the largest intellectual property pipeline of its kind, representing about $1 billion in annual research spending. This means MI will be a unified route for all of Toronto's academics and their institutions when they want to develop and commercialise a bright idea. Most importantly, investors from industry who are looking to collaborate will now be able to deal with just organisation and one IP process. MI will cover patentable ideas across a broad range of areas, and not just life sciences - the discovery pipeline in physical sciences, information and communication technology, and green technology ('cleantech') will all be funnelled through MI. MI now represents three universities, 10 academic teaching hospitals and the Ontario Institute for Cancer Research. MaRS Innovation, with support from MaRS and BioDiscovery Toronto, will advance commercialisation through industry partnerships, licensing and company creation.
  • ts chief executive is Dr Rafi Hofstein. Hofstein has been headhunted from Israel where he was chief executive of Hadasit, the technology transfer company of the Hadassah Medical Organization in Jerusalem and chair of the publicly-traded company Hadasit BioHolding. He brings this considerable experience in technology transfer to what he thinks is a groundbreaking enterprise."MaRS Innovation is a unique global initiative, and I must commend the institutional leaders in Toronto for pulling this innovation powerhouse together to strengthen commercialisation output." He adds: "I believe this is going to modernise the whole notion of tech transfer." He says the scale and diversity of MaRS Innovation's remit puts it into a league of its own. Other research clusters elsewhere in the world have attempted similar projects before, but have been thwarted by the difficulty in bringing parties together. MaRS Innovation will also help launch and grow new spin-off companies and incubate them for 2-3 years to ensure a strong commercial footing. Hofstein says MI will also fund proof of concept trials which will persuade major pharma companies to invest in their development.
  • MI has just announced its first two commercialisation deals with academic partners in the city. The first is with the Samuel Lunenfeld Research Institute of Mount Sinai Hospital to develop stem cell from umbilical cords to treat cardiovascular disease, diabetes and neurological disorders. "With the Toronto area identified as a world-leading cluster in stem cell research, we are extremely excited to have identified this technology as our first commercialisation opportunity," said Dr Hofstein.
  • "Our partnership with MaRS Innovation on developing methods for using stem cells for diseases such as diabetes will allow us to work towards advancing care for these critical conditions."
  • The second collaboration is between MI and The University of Toronto (U of T) and involves a novel sustained release formulation of nitric oxide (NO) for applications in wound healing, including diabetic ulcers. "There are 300 million diabetics worldwide, of which some 15% develop troublesome foot ulcers. This wound healing technology is extremely exciting, making it an early commercialisation opportunity that MaRS Innovation has identified as being a potential win for some 45 million diabetics globally," said Dr Hofstein.
  • "This is one of many new commercialisation ventures that will be initiated by MaRS Innovation, our partner in commercialisation of research with 13 other academic institutions across the Greater Toronto Area," said Paul Young, U of T's vice-president, Research. "We at U of T are delighted that this innovation from Dr Lee will be taken to the marketplace to the benefit of society and the economy of Ontario and Canada." By aggregating the leading edge science of its institutional members and being a one-stop commercialisation centre for industry, entrepreneurs and investors, MI could really help put Toronto and Canada on the map."MaRS Innovation is deeply committed to facilitating strategic research collaborations with industry partners, strengthening the innovation capacity of Canadian industry through adoption of new technologies, and launching a new generation of robust, high-growth Canadian companies that will become global market leaders," added Dr Hofstein. "We look forward to working closely with all of our institutional members and to continue to jointly announce exciting commercial opportunities."
  •  
    Canada has always had to fight hard to attract talent and investment. As stated in Pharmafocus.com, "MaRS Discovery District helps to foster and accelerate the growth of successful Canadian businesses." MaRS Innovation has also been launched to accelerate ideas onto the market.
Assunta Krehl

Toronto's $25 million commercialization "engine" celebrates the appointment of its Boar... - 0 views

  • MaRS Innovation is honoured to announce its permanent Board of Directors, who brings together a remarkable and broad set of experiences and networks to support the development of this dynamic partnership of Toronto research institutions.  Designed to enhance the commercial output of Toronto’s world-leading research cluster, MaRS Innovation is positioned to make a significant contribution to Canada’s innovation economy and the quality of life for Canadians and others around the world.
  • upported by the Government of Canada through the Centres of Excellence in Research and Commercialization (CECR) program, and its member institutions, MaRS Innovation is focused on converting important discoveries into a new generation of products, services and high value jobs. The newly appointed Board of Directors, which includes academic and business leaders from across Canada and the United States, has the targeted expertise to guide MaRS Innovation to deliver on this critical mission.   MaRS Innovation represents a unique collaborative model, which aggregates the exceptional discovery pipeline of 14 leading Toronto academic institutions to build a diversified portfolio of assets, and harness the economic and job creation potential of the best opportunities for Toronto, Ontario and Canada.
  • “MaRS Innovation is privileged to announce a Board of Directors of this caliber and breadth of skill,” said Mary Jo Haddad, Chair of the MaRS Innovation Board and President and CEO of The Hospital for Sick Children. “The collective experience and guidance of these individuals will be critical to developing a collaborative, integrated and agile approach to this transformational organization that will move Canada into its next phase of economic development.”
  • ...2 more annotations...
  • W. Geoffrey Beattie – Deputy Chairman & President, Woodbridge Company Limited, Thomson Reuters Corporation, Toronto Christopher C. Capelli – Vice President, Technology Based Ventures, Office of Technology Commercialization, University of Texas, M.D. Anderson Cancer Center, Houston, TX Ron Close – Information technology entrepreneur, Entrepreneur-in-Residence, MaRS, and Executive Entrepreneur-in-Residence, The Richard Ivey School of Business, The University of Western Ontario, London, ON Nicholas Darby – Formerly Director of Physical Sciences, Corporate Venture Capital, Dow Chemical Company, President, Darby & Associates Consulting LLC, Midland, MI  Mary Jo Haddad – President & CEO, The Hospital for Sick Children, Toronto Jacqueline H.R. Le Saux – Former General Counsel, North America and Corporate Secretary, Patheon, Inc., Toronto David A. Leslie - Chair, Sunnybrook Health Sciences Centre, and Former Chairman & CEO, Ernst & Young, Toronto Michael H. May – President & CEO, Rimon Therapeutics, Toronto Chandra J. Panchal – Founder, President & CEO, Axcelon Biopolymers Corp., Dollard-des-Ormeaux, QC Ilse Treurnicht – CEO, MaRS Discovery District, Toronto Donald A. Wright – President & CEO, The Winnington Capital Group Inc., Toronto
  • MaRS Innovation serves as a business accelerator platform with a single point of entry for industry partners and investors.  It will increase the scale, scope and viability of IP offerings, and the quantity and quality of deal flow from partner institutions.  MaRS Innovation will also facilitate strategic research collaborations with industry partners, strengthen the innovation capacity of Canadian industry through adoption of new technologies from its member institutions, and launch a new generation of robust, high-growth Canadian companies that will become global market leaders.   The quality of the combined discovery pipeline will catalyze and attract sources of risk capital for translational research, market validation, company formation and growth.  “MaRS Innovation represents a unique and timely platform to contribute in a meaningful way to Canada’s knowledge economy, leveraging Toronto’s remarkable research excellence.  The vision and serious commitment of its members to work together to transform our commercialization results, and the support of the Federal Government, made this possible.  The announcement of this outstanding group of leaders to the Board of Directors for MaRS Innovation is an exciting step forward,” said Ilse Treurnicht, MaRS CEO and interim Managing Director of MaRS Innovation.
  •  
    MaRS Innovation announced its permanent Board of Directors. MaRS Innovation is focused on converting important discoveries into a new generation of products, services and high value jobs.
  •  
    MaRS Innovation announced its permanent Board of Directors. MaRS Innovation is focused on converting important discoveries into a new generation of products, services and high value jobs. Feb 6, 2009
Assunta Krehl

Bootstrapping VC (The Deal Magazine) - 0 views

  • "The size of what Quebec did caught our attention," says CVCA president Gregory Smith from the association's tiny office in Toronto's MaRS Centre, a renovated 1913 hospital now a facility to house tech startups.
  •  
    Bernier is now founder and managing partner of the Teralys Capital Fund, the C$825 million ($730 million) fund-of-funds announced in April by the Quebec government and several partners.
1 - 5 of 5
Showing 20 items per page